Use the search bar to search by drug, manufacturer, or indication. You can also filter your search results by drug, manufacturer, or negotiation status.
To learn more about a specific file, click on a drug name. It will open its product card, which includes information about the manufacturer, indication (the approved use of a drug by Health Canada), and negotiation milestones.
There are 6 negotiation statuses, which reflect where the drug file is in the pCPA process:
Under consideration for negotiation
We’re considering the evidence and gathering other information to inform the negotiation approach, including eligibility for expedited negotiation pathways.
Active negotiation
Negotiation activities are underway for the drug, with our negotiation team and the manufacturer meeting regularly.
Concluded with an LOI
Negotiations ended successfully with mutually agreed-upon terms, and these terms are outlined in a letter of intent (LOI).
Concluded without agreement
Negotiating parties couldn’t agree on terms. Negotiations have ended without a pricing agreement for the drug.
Negotiation not pursued
It has been decided, in partnership with our member drug plans, not to engage in a negotiation. Typically, this is because the drug’s health technology (HTA) assessment reimbursement recommendations were negative, or “do not reimburse.” Other reasons, like the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected in an accompanying status note.
Negotiation on hold
We began negotiation activities for the drug, but they’ve since been paused. An accompanying status note indicates whether the pause was requested by the manufacturer or the pCPA.
Learn more
To learn more about our negotiation processes, or where the pCPA fits into the Canadian drug reimbursement system, consult these pages:
Inqovi (decitabine-cedazuridine)
Status:
Concluded without agreement
Manufacturer:
Taiho Pharma Canada Inc.
Indication:
Myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups, in adult patients
Last updated:
April 22, 2022
Kynmobi (apomorphine hydrochloride)
Status:
Concluded with an LOI
Manufacturer:
Sunovion Pharmaceuticals Canada Inc.
Indication:
Parkinson's disease
Last updated:
April 4, 2022
Insulin pumps and pump supplies (Insulin pumps and pump supplies)
Status:
Concluded with an LOI
Manufacturer:
Tandem Diabetes Care Canada, Inc.
Indication:
Diabetes Mellitus, Type 1 & 2
Last updated:
March 29, 2022
Status:
Concluded with an LOI
Manufacturer:
Marcan Pharmaceuticals Inc.
Indication:
Wilson's Disease
Last updated:
March 25, 2022
Status:
Concluded with an LOI
Manufacturer:
Organon Canada Inc.
Indication:
Metastatic Colorectal Cancer (mCRC); Locally Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC); Platinum-Sensitive Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; and Malignant Glioma (WHO Grade IV) - Glioblastoma
Last updated:
March 16, 2022
Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
Light chain amyloidosis (AL), newly diagnosed in adult patients (in combination with bortezomib, cyclophosphamide, and dexamethasone)
Last updated:
March 11, 2022
Status:
Concluded without agreement
Manufacturer:
Celltrion Healthcare Canada Ltd.
Indication:
Rheumatoid Arthritis
Last updated:
March 10, 2022
Insulin pumps and pump supplies (Insulin pumps and pump supplies)
Status:
Concluded with an LOI
Manufacturer:
Ypsomed Canada Inc.
Indication:
Diabetes Mellitus, Type 1 & 2
Last updated:
March 8, 2022
Insulin pumps and pump supplies (Insulin pumps and pump supplies)
Status:
Concluded with an LOI
Manufacturer:
Medtronic Canada
Indication:
Diabetes Mellitus, Type 1 & 2
Last updated:
March 8, 2022
Status:
Concluded with an LOI
Manufacturer:
Jamp Pharma Corporation
Indication:
Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis
Last updated:
March 3, 2022